Diffuse Midline Glioma, H3 K27M-Mutant Clinical Trials in Boston, Massachusetts
5 recruitingBoston, Massachusetts
Showing 1–5 of 5 trials
Recruiting
Phase 2
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+7 more
Nationwide Children's Hospital120 enrolled21 locationsNCT05843253
Recruiting
Targeted Pediatric High-Grade Glioma Therapy
Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+6 more
Nationwide Children's Hospital350 enrolled21 locationsNCT05839379
Recruiting
Phase 1
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Diffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-Mutant
Ann & Robert H Lurie Children's Hospital of Chicago36 enrolled3 locationsNCT04943848
Recruiting
Phase 2
Combination Therapy for the Treatment of Diffuse Midline Gliomas
Recurrent Diffuse Intrinsic Pontine GliomaDiffuse Intrinsic Pontine GliomaWHO Grade III Glioma+3 more
University of California, San Francisco360 enrolled32 locationsNCT05009992
Recruiting
Phase 2
Study of Olutasidenib and Temozolomide in HGG
Metastatic Brain TumorIDH1 MutationAstrocytoma, Grade IV+16 more
Rigel Pharmaceuticals60 enrolled18 locationsNCT06161974